Monday, December 04, 2017 -- By Dr. Mercola For people who don't have it, psoriasis may seem like a minor condition that may be slightly unsightly and mildly irritating. In reality, however, this can be a long-term skin condition, evidenced by patches of skin anywhere on your body that can be not just scaly and irritated but swollen and painful. It can also lead to other, more serious problems. Today, about 7.5 million people in the U.S. suffer from this chronic condition, caused by cell buildup that is not just on the surface but goes deeper, often bringing joint pain from psoriatic arthritis. Further, asthma, diabetes, heart disease and even depression have been traced back to psoriasis. Conventional treatments for psoriasis, depending on the
Friday, November 24, 2017 -- (Natural News) After battling with eczema and psoriasis for the last two decades, Hanna Sillitoe has finally found a cure. The 38-year-old from Manchester says that switching to an anti-inflammatory diet has changed her life. At one point, Sillitoe’s skin conditions were so difficult to treat, doctors suggested she try chemotherapy. Instead, Sillitoe started doing... Read More
Saturday, December 02, 2017 -- In mouse models of psoriasis, researchers found that oral administration of a synthetic vanilla extract called vanillin reduced skin inflammation.
Tuesday, August 29, 2017 -- The more the surface area of the body is covered by psoriasis, the greater the risk of death for the patient suffering from the condition, according to a new analysis by researchers in the Perelman School of Medicine at the University of Pennsylvania. The study, which published today in the Journal of Investigative Dermatology, is the […] The post Psoriasis severity linked to increased risk of death: Penn study appeared first on Outbreak News Today.
Friday, September 01, 2017 -- University of Pennsylvania researchers have determined more surface area coverage of psoriasis increases patient death risk. Perelman School of Medicine study findings published in the Journal of Investigative Dermatology outline the process implementing a disease severity measure known as Body … Read More » The post Study links psoriasis severity, death risk appeared first on Life Science Daily.
Monday, September 11, 2017 -- Scientists in the U.S. have developed compounds derived from solenopsin, the toxic constituent of fire ant venom, which helped to reduce skin thickening and inflammation in a mouse model of psoriasis, and which they suggest could be evaluated as potential new treatments for psoriasis in humans. Psoriasis is an autoimmune chronic inflammatory skin condition that affects an estimated 2.5–6 million patients in the U.S., or about 1–2% of the population. Topical treatments—primarily corticosteroids—have been the mainstay of managing mild to moderate psoriasis for 50 years. Systemic drugs including methotrexate, vitamin A derivatives, and cyclosporine, and biologic treatments including drugs that target tumor necrosis factor alpha (TNF-alpha), interleukin (L)-23, and IL-17, are used to treat more generalized and severe disease.
Friday, July 14, 2017 -- Johnson & Johnson’s Janssen Biotech has won FDA approval for the plaque psoriasis candidate Tremfya™ (guselkumab), creating a potentially blockbuster-scale competitor for several recent arrivals to market in the indication. Tremfya is indicated for adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The treatment is the first and only approved biologic designed to work by selectively blocking only interleukin (IL)-23, a cytokine shown to play a key role in plaque psoriasis. “Addressing the need for additional safe and effective plaque psoriasis therapies has been a critical area of focus at Janssen for more than 15 years,” Andrew Greenspan, M.D., vp of medical affairs at Janssen, said in a statement. Janssen licenses
Monday, November 20, 2017 -- Can the active cannabinoids in cannabis be an effective treatment for itchy and painful psoriasis? We look at the evidence in this article.
Thursday, November 16, 2017 -- A study shows that not only is psoriasis independently tied to risk of type 2 diabetes, but that the risk rises with severity of the skin disease.
Wednesday, May 24, 2017 -- It’s one of the most common immune-mediated diseases in the U.S., causing red, patchy and scaly marks on the skin. Yet the 1 to 2 percent of the population who have psoriasis are still left to wonder why. A new study builds on the genetic architecture of psoriasis, the next step toward answering what in […] The post Psoriasis: New genetic clues uncovered by University of Michigan researchers appeared first on Outbreak News Today.
Sunday, November 19, 2017 -- Psoriasis is a long-term condition that causes excess skin cells to form inflamed or scaly patches on the skin. Can aloe vera help manage the symptoms?
Friday, October 13, 2017 -- (Reuters) - Johnson & Johnson said on Friday it has received an expanded U.S. approval for its blockbuster psoriasis drug Stelara to treat adolescent patients aged 12 and over with moderate to severe cases of the unsightly skin condition.
Friday, September 15, 2017 -- (Reuters) - A European Medicines Agency (EMA) panel recommended the approval of Johnson & Johnson unit Janssen's drug, guselkumab, for the treatment of plaque psoriasis in adults.
Monday, November 20, 2017 -- Not only can stress trigger psoriasis flare-ups, but living with psoriasis can have an effect on a person's overall mental health. Learn more.
Friday, October 27, 2017 -- Researchers at the Universities of Dundee and Oxford in the U.K. are optimistic about a vaccine they have developed in the aim of treating chronic skin conditions such as psoriasis and cat hair allergies.
Thursday, September 28, 2017 -- (Reuters Health) - People with psoriasis, a chronic inflammatory disease, may be more likely than others to experience heart attacks and strokes at least in part because inflammation damages their vascular system, a recent study suggests.
Thursday, July 13, 2017 -- Heads up, Novartis, Eli Lilly and Valeant: You’ve got company in the next-gen psoriasis space. On Thursday, the FDA handed Johnson & Johnson an approval for Tremfya (guselkumab), a treatment for adults with moderate to severe plaque psoriasis.
Sunday, December 03, 2017 -- People with psoriasis may notice that their symptoms tend to get better in the summer, when they are more exposed to the sun. Does sunlight heal psoriasis?
Friday, November 10, 2017 -- (Reuters Health) - People with chronic inflammatory disorders like psoriasis and rheumatoid arthritis may have an increased risk of developing serious liver damage, a recent study suggests.
Monday, October 16, 2017 -- Johnson & Johnson’s Stelara has plenty of new competition in the adult psoriasis market, so it’s gone where many of its rivals haven’t: the adolescent population.